Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Pilots with a history of depression should not be banned from flying, a leading British psychiatrist has said.
Parents have been told by teachers they'll be reported to police and social services if children to play Call of Duty or Grand Theft Auto
TV presenter Alice Beer has said the pair received similar kidnap and rape threats just weeks before the Crimewatch star was murdered.